Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -118.67% is 160% below its 5-year average of -45.60%, near the low end of its 5-year range (-121.89%–-5.36%).
As of the fiscal period ended Tuesday, June 30, 2026. 8.53% below its 12-month average of -109.34%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -118.67%.
RETURN ON INVESTED CAPITAL (ROIC)
-118.67%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-109.34%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-63.76%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-45.60%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
-8.53%
CURRENT VS 3Y AVG
-86.11%
CURRENT VS 5Y AVG
-160.22%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-25.42%
median of 377 covered companies
CURRENT VS SECTOR MEDIAN
-366.84%
vs the sector median at left
Acumen Pharmaceuticals, Inc.
Market Cap
$153.84M
Return on Invested Capital (ROIC)
-118.67%
TTM Avg
-109.34%
3Y Avg
-63.76%
5Y Avg
-45.60%
Market Cap
$152.45M
Return on Invested Capital (ROIC)
-27.25%
TTM Avg
-49.08%
3Y Avg
-43.31%
5Y Avg
-52.54%
Market Cap
$152.16M
Return on Invested Capital (ROIC)
-165.56%
TTM Avg
-176.54%
3Y Avg
-127.81%
5Y Avg
-112.12%
Market Cap
$149.51M
Return on Invested Capital (ROIC)
-23.41%
TTM Avg
-38.99%
3Y Avg
-40.72%
5Y Avg
-30.95%
Market Cap
$162.82M
Return on Invested Capital (ROIC)
-56.53%
TTM Avg
-185.89%
3Y Avg
-125.01%
5Y Avg
-88.85%
Market Cap
$142.49M
Return on Invested Capital (ROIC)
-10.85%
TTM Avg
-101.00%
3Y Avg
-120.85%
5Y Avg
-96.47%
Market Cap
$142.11M
Return on Invested Capital (ROIC)
-50.04%
TTM Avg
-28.33%
3Y Avg
-324.90%
5Y Avg
-237.35%
Market Cap
$137.29M
Return on Invested Capital (ROIC)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$134.74M
Return on Invested Capital (ROIC)
-7.01%
TTM Avg
-1.96%
3Y Avg
-0.91%
5Y Avg
1.75%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | $153.84M | -118.67% | -109.34% | -63.76% | -45.60% |
| Anavex Life Sciences Corp. (AVXL)vs › | $152.45M | -27.25% | -49.08% | -43.31% | -52.54% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $152.16M | -165.56% | -176.54% | -127.81% | -112.12% |
| Codexis, Inc. (CDXS)vs › | $149.51M | -23.41% | -38.99% | -40.72% | -30.95% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $162.82M | -56.53% | -185.89% | -125.01% | -88.85% |
| Fortress Biotech, Inc. (FBIOP)vs › | $142.49M | -10.85% | -101.00% | -120.85% | -96.47% |
| Alpha Cognition Inc (ACOG)vs › | $142.11M | -50.04% | -28.33% | -324.90% | -237.35% |
| Freenome, Inc. (FRNM)vs › | $137.29M | N/A | N/A | N/A | N/A |
| AirSculpt Technologies, Inc. (AIRS)vs › | $134.74M | -7.01% | -1.96% | -0.91% | 1.75% |
| Compass Therapeutics, Inc. (CMPX)vs › | $172.99M | -46.59% | -39.23% | -33.74% | -53.74% |
ROIC
-118.7%
ROE
-183.4%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -118.67% |
| 2026-03-31 | -96.61% |
| 2025-12-31 | -121.89% |
| 2025-09-30 | -111.60% |
| 2025-06-30 | -97.92% |
| 2025-03-31 | -68.38% |
| 2024-12-31 | -53.94% |
| 2024-09-30 | -37.60% |
| 2024-06-30 | -28.03% |
| 2024-03-31 | -22.49% |
| 2023-12-31 | -20.57% |
| 2023-09-30 | -20.30% |
| 2023-06-30 | -30.93% |
| 2023-03-31 | -27.45% |
| 2022-12-31 | -23.96% |
| 2022-09-30 | -20.04% |
| 2022-06-30 | -15.48% |
| 2022-03-31 | -11.56% |
| 2021-12-31 | -8.70% |
| 2021-09-30 | -5.36% |
| 2021-06-30 | -16.17% |
| 2021-03-31 | -86.31% |
| 2020-12-31 | -20.79% |
